Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill

PartnershipSkyriziIcotydePositive

AI Analysis

Summary

Avere, formed from Akero executives post-buyout, has licensed a long-acting psoriasis pill from a Chinese drugmaker and is set to go public via reverse merger. The drug positions as a potential competitor to established psoriasis treatments like Skyrizi and Icotyde.

Outcome Details

Avere licensed rights to a long-acting psoriasis pill from a Chinese drugmaker

Importance:6/10

Sentiment:

0.50

licensing dealreverse mergerpsoriasislong-acting formulationcompetitive threat

Related Companies

$AKRO

Read the original article

Published by BioPharma Dive on July 14, 2026 4:00 PM

Read Original